Ypsomed, SCHOTT Collaborate with Lonza to Develop Patch Injector Solution

Ypsomed is advancing its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT and Lonza. In a joint effort, the three companies are developing a solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to bring biopharmaceuticals  in a patch injector into the clinical trial stage and to the market.

Ypsomed has entered into a collaboration with SCHOTT and Lonza to be able to offer the YpsoDose patch injector platform, which is used for the subcutaneous self-administration of high volumes of pharmaceuticals, as a fully integrated solution. The three partners are cooperating to develop all the necessary components and manufacturing processes. This will enable customers to enter into clinical trials quicker with their drugs - often sensitive biopharmaceuticals - and commercialize them in less time. The comprehensive solution includes a ready-to-use cartriQ® glass cartridge from SCHOTT as the primary packaging for the drug, the YpsoDose patch injector platform from Ypsomed, and the processes for filling, assembly and testing of the final product by Lonza Drug Product Services (DPS).

SCHOTT develops and supplies 10ml ready-to-use cartriQ® cartridges for the YpsoDose. These cartridges require fewer process steps during filling than conventional cartridges. Lonza Drug Product Services implements a filling and assembly process for YpsoDose in Stein (Switzerland) to provide short implementation times for customers.

"With this new development, for which we have also made investments at our Swiss site, we are making it possible for us to jointly optimise processes for pharmaceutical companies. At the same time, we are creating completely new possibilities in the area of self-medication in terms of drug safety and user-friendliness. This is fully in line with our aim of always acting in the best possible way for the benefit of human health," Andreas Reisse, Head of SCHOTT Pharmaceutical Systems, said.

"The know-how and expertise of Lonza DPS in the development, manufacturing and testing of formulations and sterile products for subcutaneous administration is the ideal basis to enable our pharmaceutical and biotech customers to develop and commercialise the YpsoDose patch injector," Prof. Dr. Hanns-Christian Mahler, Head of Lonza Drug Product Services said.